These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18343562)

  • 1. Management of the hormone sensitivity of prostate cancer: where are we now?
    Alcaraz A
    Eur Urol; 2008 Aug; 54(2):247-50; discussion 250-1. PubMed ID: 18343562
    [No Abstract]   [Full Text] [Related]  

  • 2. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

  • 3. Hormone-refractory prostate cancer: what have we learned?
    Wirth MP
    BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
    [No Abstract]   [Full Text] [Related]  

  • 4. Global update on the use of hormonal therapy for the management of high-risk prostate cancer: introduction.
    Gomella LG
    BJU Int; 2007 Jan; 99 Suppl 1():1. PubMed ID: 17229158
    [No Abstract]   [Full Text] [Related]  

  • 5. [Somatostatin analogs in the combined treatment of patients with hormone-resistant prostate cancer].
    Kaprin AD; Gafanov PA; Fastovets SV
    Vopr Onkol; 2009; 55(4):474-6. PubMed ID: 19947374
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate cancer drugs. Making sense of the options.
    Mayo Clin Health Lett; 2003 Aug; 21(8):4-5. PubMed ID: 12971308
    [No Abstract]   [Full Text] [Related]  

  • 7. Managing prostate cancer: the role of hormone therapy.
    Ramirez ML; Keane TE; Evans CP
    Can J Urol; 2007 Dec; 14 Suppl 1():10-8. PubMed ID: 18163939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer.
    Pitts WR
    BJU Int; 2004 May; 93(7):1119-20. PubMed ID: 15142186
    [No Abstract]   [Full Text] [Related]  

  • 9. How early is early: androgen deprivation for prostate-specific antigen relapse in prostate cancer.
    Duchesne GM; Syme R; Howell D
    J Clin Oncol; 2006 Jun; 24(18):2964; author reply 2965. PubMed ID: 16782936
    [No Abstract]   [Full Text] [Related]  

  • 10. Monotherapy versus combined androgen blockade in patients with advanced prostate cancer.
    Errejon A; Crawford ED
    Cancer; 2002 Jul; 95(2):209-10. PubMed ID: 12124816
    [No Abstract]   [Full Text] [Related]  

  • 11. [Basic and clinical characteristics of flutamide].
    Suzuki K; Nakazato H; Kurokawa K; Yamanaka H
    Nihon Rinsho; 2000 Jul; 58 Suppl():211-5. PubMed ID: 11022716
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.
    Koutsilieris M; Dimopoulos T; Milathianakis C; Bogdanos J; Karamanolakis D; Pissimissis N; Halapas A; Lembessis P; Papaioannou A; Sourla A
    BJU Int; 2007 Jul; 100 Suppl 2():60-2. PubMed ID: 17594363
    [No Abstract]   [Full Text] [Related]  

  • 13. Multiple intracrine hormonal targets in the prostate: opportunities and challenges.
    Labrie F
    BJU Int; 2007 Jul; 100 Suppl 2():48-51. PubMed ID: 17594360
    [No Abstract]   [Full Text] [Related]  

  • 14. Key targets of hormone treatment of prostate cancer. Part I: the androgen receptor and steroidogenic pathways.
    Pitts WR
    BJU Int; 2009 Nov; 104(9):1304. PubMed ID: 19824968
    [No Abstract]   [Full Text] [Related]  

  • 15. Mechanisms leading to the development of hormone-resistant prostate cancer.
    Kasper S; Cookson MS
    Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status and prospects of androgen depletion therapy for prostate cancer.
    Akaza H
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evolution of endocrine therapy for prostate cancer].
    Igawa T; Saito Y
    Nihon Rinsho; 2000 Jul; 58 Suppl():176-81. PubMed ID: 11022709
    [No Abstract]   [Full Text] [Related]  

  • 18. [Role of hormonotherapy in the treatment of metastatic prostate cancer].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S332-7. PubMed ID: 19070812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy.
    Palma D; Pickles T
    Cancer; 2008 May; 112(10):2322-3; author reply 2323. PubMed ID: 18327816
    [No Abstract]   [Full Text] [Related]  

  • 20. The benefits of early androgen blockade.
    Maroni PD; Crawford ED
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.